Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Betaine in Patients With Nonalcoholic Steatohepatitis

This study has been completed.
University of Florida
Orphan Medical
Information provided by:
Mayo Clinic Identifier:
First received: December 21, 2007
Last updated: April 6, 2015
Last verified: April 2015
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.

Condition Intervention Phase
Nonalcoholic Steatohepatitis
Drug: Cystadane
Drug: Identical Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled Trial of Betaine in Patients With Nonalcoholic Steatohepatitis (NASH)

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • changes in degree of steatosis, necroinflammatory activity and fibrosis in liver biopsy. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Secondary end-points will be changes in liver test results and health related quality of life. [ Time Frame: 1 year ]

Enrollment: 26
Study Start Date: January 2003
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Cystadane Drug: Cystadane
Betaine 20 mg a day or identical placebo for 1 year.
Placebo Comparator: Identical Placebo Drug: Identical Placebo


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult males or females, age 18 - 70 (inclusive) with NASH.
  • Abnormal aminotransferase levels (1.5x normal) on at least two occasions at less three months apart.
  • Histologic evidence of steatohepatitis on liver biopsy performed within six months of entry.
  • Absence of sustained alcohol ingestion (less than 20 g/d in women or 30 g/d in men).
  • Compensated liver disease and blood cell counts within the following limits: Hb > 12 gr/dl, platelets > 120,000/mm3, and WBC > 3,000/mm3
  • TSH (thyroid-stimulating hormone) within normal limits of testing laboratory.
  • Appropriate exclusion of other liver disease such as viral, autoimmune and metabolic/hereditary liver disease.
  • If a history of diabetes, a hemoglobin A1C < 10.0%.
  • Alpha-fetoprotein in normal range (obtained within the previous year), or if greater than normal, the patient requires a negative ultrasound for hepatocellular carcinoma within prior 3 months.
  • Sexually active female patients of childbearing potential must practice adequate contraception during the treatment period and for 6 months after discontinuation of therapy. A pregnancy test obtained at entry prior to the initiation of treatment must by negative. Female patients must not be breast-feeding.
  • Sexually active male patients must practice acceptable methods of contraception during the treatment period and for 6 months after discontinuation of therapy.
  • Written informed consent for participation in this study.

Exclusion Criteria:

  • Treatment with any experimental drug for NASH, betaine, ursodeoxycholic acid (URSO), methionine, rosiglitazone, metformin, pioglitazone, or vitamin E within 3 months of enrollment or at time of pre-entry liver biopsy. (Patients with diabetes and on stable medical management for six months prior to entry and an anticipated stable program throughout the study will be eligible. Medications that may be used include insulin, biguanides, thiazolidnediones, metformin, and sulfonylureas. Patients with hyperlipidemia on a medical program for control of lipids who have had a change in drug treatment in the preceding six months or with anticipated changes in the year of the study will also be eligible.)
  • Any cause for the liver disease based on patient history and biopsy (where applicable) other than NASH
  • Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy.
  • Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study such as significant cardiovascular dysfunction or chronic obstructive pulmonary disease requiring specific therapy
  • Pregnancy or breastfeeding.
  • Unwillingness of patient and/or partner to use contraception during treatment.
  • Previous malignant disease (other than non-melanoma skin cancer) in the previous two years.
  • Substance abuse, such as alcohol, I.V. drugs and inhaled drugs.
  • Any other conditions that in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the protocol.
  • Lactose intolerant patient since placebo preparation contains lactose.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00586911

United States, Florida
University of Florida at Gainesville
Gainesville, Florida, United States, 32610
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
University of Florida
Orphan Medical
Principal Investigator: Keith D Lindor, MD Mayo Clinic
  More Information

Responsible Party: Dr. Keith D. Lindor, MD / PI, Mayo Clinic Identifier: NCT00586911     History of Changes
Other Study ID Numbers: 458-00
Study First Received: December 21, 2007
Last Updated: April 6, 2015

Keywords provided by Mayo Clinic:
Nonalcoholic Steatohepatitis

Additional relevant MeSH terms:
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases
Gastrointestinal Agents
Lipotropic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on April 25, 2017